清肝化瘀颗粒联合TACE术对原发性肝癌患者无进展生存期和生存质量的影响

Effect of Qinggan Huayu Granule Combined with TACE on Progression-free Survival and Quality of Life in Patients with Primary Hepatocellular Carcinoma

目的探讨清肝化瘀颗粒联合射频消融对原发性肝癌介入术后患者无进展生存期和生存质量的影响。方法选择本科收治的46例精原发性肝癌介入术后患者,将所有患者分为2组,即观察组予以清肝化瘀颗粒联合射频消融治疗措施,对照组予以射频消融治疗措施,每组各23例。对于两组患者的无进展生存期、肝功能和生存质量进行比较。结果与对照组比较,观察组的PFS(145.06±7.84)d、中位无进展生存时间(m PFS)145d以及半年生存率91.30%,均升高明显,差异具统计学意义(P<0.05)。治疗前,两组患者的肝功能及生存质量各项评分无差异性(P>0.05);治疗后,与对照组比较,观察组ALT(66.13±41.82)U/L,AST(54.67±28.32)U/L,中医证候评分(18.05±1.33)分,均降低明显,KPS评分(74.15±6.22)分则增加明显,差异具统计学意义(P<0.05)。结论清肝化瘀颗粒联合射频消融可提高原发性肝癌介入术后患者无进展生存期,改善生存质量。

Objective： To study the effect of Qinggan Huayu Granule combined with radiofrequency ablation on progression -free survival and quality of life in patients with primary liver cancer after intervention operation. Meth- ods： 46 patients who were treated in our department were chosen and divided into a group treated with Qinggan Huayu Granule combined with radiofrequency ablation and a control group treated with radiofrequency ablation, 23 cases per group. The progression - free survival, liver function and quality of life of both groups were compared. Results ： Corn- pared with the control group, the PFS （ 145.06 ±7.84） d, the median progression - free survival time （mPFS） and the 91.30% half- year survival rate of the observation group significantly increased, and the difference was statistical significance （ P 〈 0.05 ） The There was no significant difference in the liver function and quality of life between the two groups before the treatment （P 〉0.05）. After the treatment, the levels of ALT （66.13 ±41.82） U/L, AST （54.67 ±28.32） U/L, TCM syndrome score （ 18.05 ± 1.33 ） score （74.15 ± 6.22） points increased significantly, an poi d th nts of the observation group significantly decreased, KPS e difference was statistical significance （P 〈 0.05 ）. Con- clusion ： Qinggan Huayu Granule combined with radiofrequency ablation can improve the progression - free survival and the quality of life of the patients with primary liver cancer after intervention operation .